©Author(s) (or their employer(s)) 2026.
World J Gastroenterol. Mar 7, 2026; 32(9): 114200
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114200
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114200
Table 1 Clinicopathological characteristics of patients, n (%)
| Characteristics | Training cohort (n = 2496) | Validation cohort (n = 1293) | P value |
| Sex | 0.518 | ||
| Male | 1513 (60.6) | 769 (59.5) | |
| Female | 983 (39.4) | 524 (40.5) | |
| Age, mean (SD) | 65.64 (10.14) | 60.73 (10.33) | < 0.001 |
| Height, mean (SD) | 166.37 (9.16) | 167.52 (28.99) | 0.069 |
| Weight, mean (SD) | 66.58 (12.43) | 66.25 (11.90) | 0.432 |
| Smoking | < 0.001 | ||
| Negative | 1370 (54.9) | 889 (68.8) | |
| Positive | 1126 (45.1) | 404 (31.2) | |
| Drinking | 0.853 | ||
| Negative | 1963 (78.6) | 1021 (79.0) | |
| Positive | 533 (21.4) | 272 (21.0) | |
| Ileus | < 0.001 | ||
| Negative | 2139 (85.7) | 1181 (91.3) | |
| Positive | 357 (14.3) | 112 (8.7) | |
| Diabetes | < 0.001 | ||
| Negative | 2338 (93.7) | 1159 (89.6) | |
| Positive | 158 (6.3) | 134 (10.4) | |
| Hypertension | < 0.001 | ||
| Negative | 2304 (92.3) | 1013 (78.3) | |
| Positive | 192 (7.7) | 280 (21.7) | |
| Differentiation | < 0.001 | ||
| Well | 7 (0.3) | 173 (13.4) | |
| Moderate | 2060 (82.5) | 1023 (79.1) | |
| Poor | 429 (17.2) | 97 (7.5) | |
| Signet-ring cell carcinoma | 0.022 | ||
| Negative | 2444 (97.9) | 1280 (99.0) | |
| Positive | 52 (2.1) | 13 (1.0) | |
| Mucinous carcinoma | < 0.001 | ||
| Negative | 2060 (82.5) | 1132 (87.5) | |
| Positive | 436 (17.5) | 161 (12.5) | |
| Location | < 0.001 | ||
| Rectum | 1232 (49.4) | 797 (61.6) | |
| Left colon | 684 (27.4) | 267 (20.6) | |
| Right colon | 580 (23.2) | 229 (17.7) | |
| Vascular cancer embolus | 0.051 | ||
| Negative | 2260 (90.5) | 1196 (92.5) | |
| Positive | 236 (9.5) | 97 (7.5) | |
| Perineural invasion | 0.397 | ||
| Negative | 2056 (82.4) | 1080 (83.5) | |
| Positive | 440 (17.6) | 213 (16.5) | |
| Stage | < 0.001 | ||
| II | 1285 (51.5) | 780 (60.3) | |
| III | 1211 (48.5) | 513 (39.7) | |
| Microsatellite stability | < 0.001 | ||
| MSI-H | 178 (7.1) | 30 (2.3) | |
| MSS | 804 (32.2) | 504 (39.0) | |
| No detection | 1514 (60.7) | 759 (58.7) | |
| Recurrence or metastasis site | 0.002 | ||
| No recurrence or metastasis | 2158 (86.5) | 1171 (90.6) | |
| Liver | 121 (4.8) | 52 (4.0) | |
| Lung | 101 (4.0) | 32 (2.5) | |
| Recurrence | 25 (1.0) | 14 (1.1) | |
| Abdominal pelvic and viscera in abdominal pelvic | 46 (1.8) | 16 (1.2) | |
| Others (brain, bone, superficial lymph nodes, etc.) | 45 (1.8) | 8 (0.6) | |
| Adjuvant chemotherapy type | < 0.001 | ||
| Folfox | 134 (5.4) | 254 (19.6) | |
| Xelox | 981 (39.3) | 391 (30.2) | |
| Monotherapy | 105 (4.2) | 191 (14.8) | |
| No adjuvant chemotherapy | 1276 (51.1) | 457 (35.3) |
- Citation: Du FQ, Liu JL, Mai LD, Han XH, Song WJ, Yang D, Zhang QJ, Zhang R, Liu YL, Tong JX. Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer. World J Gastroenterol 2026; 32(9): 114200
- URL: https://www.wjgnet.com/1007-9327/full/v32/i9/114200.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i9.114200